187 related articles for article (PubMed ID: 27777607)
1. Effect of mirtazapine versus selective serotonin reuptake inhibitors on benzodiazepine use in patients with major depressive disorder: a pragmatic, multicenter, open-label, randomized, active-controlled, 24-week trial.
Hashimoto T; Shiina A; Hasegawa T; Kimura H; Oda Y; Niitsu T; Ishikawa M; Tachibana M; Muneoka K; Matsuki S; Nakazato M; Iyo M
Ann Gen Psychiatry; 2016; 15():27. PubMed ID: 27777607
[TBL] [Abstract][Full Text] [Related]
2. Serum brain-derived neurotrophic factor, Val66Met polymorphism and open-label SSRI treatment response in Major Depressive Disorder.
Smit AJT; Wu GWY; Rampersaud R; Reus VI; Wolkowitz OM; Mellon SH
Psychoneuroendocrinology; 2024 Jul; 165():107045. PubMed ID: 38636352
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness of mirtazapine as add-on to paroxetine
Xiao L; Zhu X; Gillespie A; Feng Y; Zhou J; Chen X; Gao Y; Wang X; Ma X; Gao C; Xie Y; Pan X; Bai Y; Xu X; Wang G; Chen R
Psychol Med; 2021 May; 51(7):1166-1174. PubMed ID: 31931894
[TBL] [Abstract][Full Text] [Related]
4. Non response at week 4 as clinically useful indicator for antidepressant combination in major depressive disorder. A sequential RCT.
Kato M; Takekita Y; Koshikawa Y; Sakai S; Bandou H; Nishida K; Sunada N; Onohara A; Hatashita Y; Serretti A; Kinoshita T
J Psychiatr Res; 2017 Jun; 89():97-104. PubMed ID: 28213170
[TBL] [Abstract][Full Text] [Related]
5. Other Antidepressants.
Schwasinger-Schmidt TE; Macaluso M
Handb Exp Pharmacol; 2019; 250():325-355. PubMed ID: 30194544
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and tolerability of mirtazapine in treating major depressive disorder with anxiety symptoms: an 8-week open-label randomised paroxetine-controlled trial.
Kim JE; Yoon SJ; Kim J; Jung JY; Jeong HS; Cho HB; Shin E; Lyoo IK; Kim TS
Int J Clin Pract; 2011 Mar; 65(3):323-9. PubMed ID: 21314870
[TBL] [Abstract][Full Text] [Related]
7. Remission with mirtazapine and selective serotonin reuptake inhibitors: a meta-analysis of individual patient data from 15 controlled trials of acute phase treatment of major depression.
Thase ME; Nierenberg AA; Vrijland P; van Oers HJ; Schutte AJ; Simmons JH
Int Clin Psychopharmacol; 2010 Jul; 25(4):189-98. PubMed ID: 20531012
[TBL] [Abstract][Full Text] [Related]
8. Saliva levels of 3-methoxy-4-hydroxyphenylglycol and clinical efficacy of mirtazapine or selective serotonin reuptake inhibitors in patients with major depression.
Egami M; Imamura Y; Nabeta H; Mizoguchi Y; Yamada S
Hum Psychopharmacol; 2013 Jan; 28(1):7-14. PubMed ID: 23124792
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of add on low-dose mirtazapine in depression.
Matreja PS; Badyal DK; Deswal RS; Sharma A
Indian J Pharmacol; 2012 Mar; 44(2):173-7. PubMed ID: 22529470
[TBL] [Abstract][Full Text] [Related]
10. The impact of chronic depression on acute and long-term outcomes in a randomized trial comparing selective serotonin reuptake inhibitor monotherapy versus each of 2 different antidepressant medication combinations.
Sung SC; Haley CL; Wisniewski SR; Fava M; Nierenberg AA; Warden D; Morris DW; Kurian BT; Trivedi MH; Rush AJ;
J Clin Psychiatry; 2012 Jul; 73(7):967-76. PubMed ID: 22687487
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of mirtazapine in major depressive disorder patients after SSRI treatment failure: an open-label trial.
Fava M; Dunner DL; Greist JH; Preskorn SH; Trivedi MH; Zajecka J; Cohen M
J Clin Psychiatry; 2001 Jun; 62(6):413-20. PubMed ID: 11465517
[TBL] [Abstract][Full Text] [Related]
12. Mirtazapine versus selective serotonin reuptake inhibitors.
Thompson C
J Clin Psychiatry; 1999; 60 Suppl 17():18-22; discussion 46-8. PubMed ID: 10446737
[TBL] [Abstract][Full Text] [Related]
13. Hyponatremia associated with selective serotonin reuptake inhibitors, mirtazapine, and venlafaxine in Korean patients with major depressive disorder.
Jung YE; Jun TY; Kim KS; Bahk WM
Int J Clin Pharmacol Ther; 2011 Jul; 49(7):437-43. PubMed ID: 21726494
[TBL] [Abstract][Full Text] [Related]
14. Combining mirtazapine with SSRIs or SNRIs for treatment-resistant depression: the MIR RCT.
Kessler D; Burns A; Tallon D; Lewis G; MacNeill S; Round J; Hollingworth W; Chew-Graham C; Anderson I; Campbell J; Dickens C; Macleod U; Gilbody S; Davies S; Peters TJ; Wiles N
Health Technol Assess; 2018 Nov; 22(63):1-136. PubMed ID: 30468145
[TBL] [Abstract][Full Text] [Related]
15. Optimising first- and second-line treatment strategies for untreated major depressive disorder - the SUN☺D study: a pragmatic, multi-centre, assessor-blinded randomised controlled trial.
Kato T; Furukawa TA; Mantani A; Kurata K; Kubouchi H; Hirota S; Sato H; Sugishita K; Chino B; Itoh K; Ikeda Y; Shinagawa Y; Kondo M; Okamoto Y; Fujita H; Suga M; Yasumoto S; Tsujino N; Inoue T; Fujise N; Akechi T; Yamada M; Shimodera S; Watanabe N; Inagaki M; Miki K; Ogawa Y; Takeshima N; Hayasaka Y; Tajika A; Shinohara K; Yonemoto N; Tanaka S; Zhou Q; Guyatt GH;
BMC Med; 2018 Jul; 16(1):103. PubMed ID: 29991347
[TBL] [Abstract][Full Text] [Related]
16. [Use of antidepressant drugs in schizophrenic patients with depression].
Micallef J; Fakra E; Blin O
Encephale; 2006; 32(2 Pt 1):263-9. PubMed ID: 16910628
[TBL] [Abstract][Full Text] [Related]
17. Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis.
Furukawa TA; Cipriani A; Cowen PJ; Leucht S; Egger M; Salanti G
Lancet Psychiatry; 2019 Jul; 6(7):601-609. PubMed ID: 31178367
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and Tolerability of Generic Mirtazapine (Mirtax) for Major Depressive Disorder: Multicenter, Open-label, Uncontrolled, Prospective Study.
Song HR; Bahk WM; Woo YS; Jeong JH; Kwon YJ; Seo JS; Kim W; Kim MD; Shin YC; Lee SY; Min KJ
Clin Psychopharmacol Neurosci; 2015 Aug; 13(2):144-9. PubMed ID: 26243840
[TBL] [Abstract][Full Text] [Related]
19. Validation of the predictive value of BDNF -87 methylation for antidepressant treatment success in severely depressed patients-a randomized rater-blinded trial.
Maier HB; Neyazi A; Bundies GL; Meyer-Bockenkamp F; Bleich S; Pathak H; Ziert Y; Neuhaus B; Müller FJ; Pollmann I; Illig T; Mücke S; Müller M; Möller BK; Oeltze-Jafra S; Kacprowski T; Voges J; Müntefering F; Scheiber J; Reif A; Aichholzer M; Reif-Leonhard C; Schmidt-Kassow M; Hegerl U; Reich H; Unterecker S; Weber H; Deckert J; Bössel-Debbert N; Grabe HJ; Lucht M; Frieling H
Trials; 2024 Apr; 25(1):247. PubMed ID: 38594753
[TBL] [Abstract][Full Text] [Related]
20. Edivoxetine compared to placebo as adjunctive therapy to selective serotonin reuptake inhibitors in the prevention of symptom re-emergence in major depressive disorder.
Oakes TM; Dellva MA; Waterman K; Greenbaum M; Poppe C; Goldberger C; Ahl J; Perahia DG
Curr Med Res Opin; 2015 Jun; 31(6):1179-89. PubMed ID: 25894953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
